The American College of Allergy, Asthma and Immunology holds its annual scientific meeting from November 12 to 16 in Phoenix, Arizona, bringing clinicians together to examine targeted therapies and practice-changing data.
- Targeted treatments: New biologic drugs and oral medications are offering better control for severe allergic conditions like chronic hives and hereditary swelling attacks.
- Childhood conditions: Researchers are presenting fresh data on managing pediatric food-related esophageal inflammation and combined nasal sprays for seasonal allergies.
- Environmental links: Recent investigations track how early-life wildfire smoke exposure shapes childhood asthma risks and sleep patterns in atopic dermatitis.
The Clinical Advisor and Medical Professionals Reference teams are on-site in Phoenix to report on the latest clinical news and updates. The gathering serves allergists, immunologists, nurse practitioners, physician associates, and advanced practice providers.
This year’s scientific program features research addressing recognizable clinical dilemmas alongside breakthrough targeted therapies. Sessions also incorporate health equity topics affecting diverse patient populations.
Reporting spotlights therapeutic advances in biologic and oral targeted therapies. Findings cover the efficacy and safety of treatments for chronic inducible urticaria.
Specialists are also reviewing updated data on prophylaxis for hereditary angioedema attacks. Translating this evidence into daily practice remains a core priority for meeting attendees.
Pediatric populations receive dedicated focus through research sessions centered on treating eosinophilic esophagitis. Investigators are also presenting data on combined intranasal therapies used for allergic rhinitis.
Emerging research evaluates glucagon-like peptide-1 receptor agonists for asthma outcomes in adults with obesity. Public health and environmental factors take center stage as well.
Coverage highlights the impact of prenatal wildfire smoke exposure on childhood asthma risk. Teams are also tracking heightened odds of sleep disruption among children diagnosed with atopic dermatitis.
| Focus Area | Clinical Topic | Target Population |
|---|---|---|
| Urticaria & Angioedema | Biologic efficacy and attack prophylaxis | Adults and adolescents |
| Pediatric Allergy | Eosinophilic esophagitis & rhinitis | Children |
| Metabolic Health | GLP-1 receptor agonists for asthma | Adults with obesity |
Rounding out the reporting is a case study identifying a hidden fish allergen. The allergen triggered anaphylaxis following energy drink consumption.
The Clinical Advisor and MPR websites and social media pages provide daily news reports, expert interviews, and late-breaking abstract highlights directly from the meeting.
- American College of Allergy, Asthma and Immunology. ACAAI 2026 Annual Scientific Meeting Program.
- The Clinical Advisor. On-site coverage and clinical updates from Phoenix, Arizona.
- Medical Professionals Reference (MPR). Late-breaking abstract highlights and specialty reporting.
